시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 섬유아세포 성장인자 수용체 억제제 시장 분석과 예측(-2034년) : 유형, 제품, 용도, 최종 사용자, 기술, 프로세스, 전개, 컴포넌트, 기능
Fibroblast Growth Factor Receptor Inhibitor Market Analysis and Forecast to 2034: Type, Product, Application, End User, Technology, Process, Deployment, Component, Functionality
상품코드 : 1720661
리서치사 : Global Insight Services LLC
발행일 : 2025년 05월
페이지 정보 : 영문 368 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,750 ￦ 6,606,000
Single User License help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능하며, 인쇄는 가능합니다.
US $ 5,750 ￦ 7,997,000
Site License help
PDF, Excel 보고서를 동일 기업(국가)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,750 ￦ 9,387,000
Enterprise License help
PDF, Excel 보고서를 동일 기업의 전 세계 모든분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

세계의 섬유아세포 성장인자 수용체 억제제 시장은 2024년 1억 6,420만 달러에서 2034년까지 4억 9,290만 달러로 확대되어 약 11.4%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다 이 시장은 암과 유전성 질환에서 중요한 FGFR 경로를 표적으로하는 치료제에 초점을 맞추었습니다. 시장은 암 이환율의 상승과 맞춤형 치료에 중점을 둔 정밀의료의 진보에 의해 견인되고 있습니다. 주요 기업은 유효성과 안전성을 높이기 위해 조사와 임상시험에 투자하고 있으며 경쟁력 있는 혁신을 촉진하고 있습니다.

시장 개요:

섬유아세포 성장인자 수용체(FGFR) 억제제 시장은 주로 암의 이환율의 상승과 표적요법의 진보에 견인되어 큰 성장이 예상되고 있습니다. 또한 암 영역이 주요 시장 부문으로 부상하고 있습니다. 새로운 하위 부문은 치료 효과를 높이고 약물 내성을 극복 할 수 있기 때문에지지를 모으는 병용 요법의 개발을 포함합니다. 차세대 시퀀싱 기술의 통합으로 환자의 층별화가 더욱 정교해지고, 치료 성적이 향상되어 다양한 종양학 용도에 있어서의 FGFR 억제제의 채용이 촉진될 것으로 기대되고 있습니다.

시장 세분화
유형 저분자 억제제, 단일클론항체
제품 경구약, 주사약
용도 암 치료, 염증성 질환, 유전자 질환
최종 사용자 병원, 전문 클리닉, 연구 기관, 제약 회사
기술 표적요법, 병용요법
프로세스 신약, 임상시험, 상업화
배포 자사 제조, 수탁 제조
구성요소 원약, 부형제
기능 수용체 결합, 신호전달 억제

섬유아세포 성장인자 수용체(FGFR) 억제제 시장은 암 표적 치료에 주력하는 제약 대기업에 의해 큰 점유율을 차지하고 있는 것이 특징입니다. 지역별로는 북미가 견고한 헬스 케어 인프라와 연구 투자에 지지되어 시장 도입으로 주도적인 지위를 유지하고 있는 한편, 아시아태평양은 의료비와 의식의 고조로부터 관심이 급증하고 있습니다.

경쟁 구도은 Novartis, AstraZeneca, Bayer 등 FGFR 억제제 포트폴리오를 혁신하고 확대하기 위해 연구 개발에 많은 투자를 하고 있는 주세에 의해 영향을 받고 있습니다. 향후 FGFR 억제제 시장은 바이오테크놀러지와 맞춤형 의료의 진보에 견인되어 크게 성장할 것으로 보입니다.

동향과 촉진요인:

섬유아세포 성장인자 수용체(FGFR) 억제제 시장은 정밀의료와 표적암 치료의 진보에 힘입어 강력한 성장을 이루고 있습니다. FGFR 억제제는 종양학적 치료에서 중요한 요소로서 지지를 모으고 있습니다. 각사가 치료 포트폴리오를 확대해, 의약품 개발의 타임라인을 빨리 하려고 하고 있기 때문에 전략적인 제휴나 협력 관계도 태어나고 있습니다. 또한, 규제 당국은 혁신적인 암 치료에 대한 긴급의 필요성을 인식해, 승인 프로세스를 합리화하고 있습니다. 헬스케어의 인프라가 확대해 암 치료의 개선에 점점 초점이 맞추어지고 있는 신흥 시장에도 찬스는 풍부하게 있습니다.

억제요인과 도전:

섬유 아세포 성장인자 수용체(FGFR) 억제제 시장은 현재 몇 가지 중요한 억제요인과 문제에 직면하고 있습니다. 첫 번째 과제는 의약품 개발과 임상시험에 드는 비용이 높으며 중소기업에게는 엄청난 부담이 될 수 있습니다. 이 경제적 부담은 기술 혁신을 제한하고 새로운 치료의 도입을 지연시킵니다. 게다가, 엄격한 승인 프로세스가 시장 출시까지의 시간을 늘리고 비용이 부풀어 오르기 때문에 규제상의 장애물도 엄청난 일입니다. 또한, 부작용의 가능성도 있어, 이것이 환자에게의 보급을 방해해, 규제 당국의 감시를 강화하게 됩니다. 시장 침투는 더 적은 부작용으로 유사한 효과를 제공하는 대체 요법과의 경쟁에 의해 더욱 방해받습니다. 마지막으로 의료 서비스 제공업체와 환자들 사이에 인식과 이해가 부족하여 수요를 억제하고 FGFR 억제제의 채용을 지연시킬 수 있습니다. 이러한 과제는 전체적으로 시장 성장과 접근성을 저해합니다.

목차

제1장 섬유아세포 성장인자 수용체 억제제 시장 개요

제2장 주요 요약

제3장 시장에 관한 중요 인사이트

제4장 섬유아세포 성장인자 수용체 억제제 시장 전망

제5장 섬유아세포 성장인자 수용체 억제제 시장 전략

제6장 섬유아세포 성장인자 수용체 억제제 시장 규모

제7장 섬유아세포 성장인자 수용체 억제제 시장 : 유형별

제8장 섬유아세포 성장인자 수용체 억제제 시장 : 제품별

제9장 섬유아세포 성장인자 수용체 억제제 시장 : 용도별

제10장 섬유아세포 성장인자 수용체 억제제 시장 : 최종 사용자별

제11장 섬유아세포 성장인자 수용체 억제제 시장 : 기술별

제12장 섬유아세포 성장인자 수용체 억제제 시장 : 프로세스별

제13장 섬유아세포 성장인자 수용체 억제제 시장 : 전개별

제14장 섬유아세포 성장인자 수용체 억제제 시장 : 컴포넌트별

제15장 섬유아세포 성장인자 수용체 억제제 시장 : 기능별

제16장 섬유아세포 성장인자 수용체 억제제 시장 : 지역별

제17장 경쟁 구도

제18장 기업 프로파일

JHS
영문 목차

영문목차

Fibroblast Growth Factor Receptor Inhibitor Market is anticipated to expand from $164.2 million in 2024 to $492.9 million by 2034, growing at a CAGR of approximately 11.4%. The market focuses on therapeutics targeting FGFR pathways, crucial in cancer and genetic disorders. These inhibitors offer targeted treatment options, disrupting aberrant signaling linked to tumor growth and disease progression. The market is driven by rising cancer prevalence and advancements in precision medicine, emphasizing personalized therapies. Key players are investing in research and clinical trials to enhance efficacy and safety, fostering competitive innovation. Regulatory approvals and strategic collaborations further propel market growth, presenting lucrative opportunities in oncology and rare disease treatment landscapes.

Market Overview:

The Fibroblast Growth Factor Receptor (FGFR) Inhibitor Market is poised for substantial growth, primarily driven by the rising incidence of cancer and advancements in targeted therapies. The oncology segment emerges as the leading market segment, propelled by the increasing prevalence of cancers such as bladder, lung, and gastric, where FGFR mutations are prevalent. This segment's dominance is underpinned by the demand for precision medicine and the efficacy of FGFR inhibitors in targeting specific cancer pathways. Emerging sub-segments include the development of combination therapies, which are gaining traction due to their potential to enhance treatment efficacy and overcome drug resistance. Additionally, the rise of personalized medicine and biomarker-driven therapies is likely to impact the market significantly. The integration of next-generation sequencing technologies is further expected to refine patient stratification, enhancing the therapeutic outcomes and driving the adoption of FGFR inhibitors across diverse oncology applications.

Market Segmentation
TypeSmall Molecule Inhibitors, Monoclonal Antibodies
ProductOral Drugs, Injectable Drugs
ApplicationCancer Treatment, Inflammatory Diseases, Genetic Disorders
End UserHospitals, Specialty Clinics, Research Institutes, Pharmaceutical Companies
TechnologyTargeted Therapy, Combination Therapy
ProcessDrug Discovery, Clinical Trials, Commercialization
DeploymentIn-house Manufacturing, Contract Manufacturing
ComponentActive Pharmaceutical Ingredients, Excipients
FunctionalityReceptor Binding, Signal Transduction Inhibition

The Fibroblast Growth Factor Receptor (FGFR) Inhibitor Market is characterized by a significant share dominated by pharmaceutical giants focusing on targeted cancer therapies. The market is segmented by drug type and application, with oncology leading the charge due to the rising prevalence of cancers and the growing demand for precision medicine. Geographically, North America maintains a leading position in market adoption, bolstered by robust healthcare infrastructure and research investments, while the Asia-Pacific region shows a burgeoning interest due to increasing healthcare expenditure and awareness.

The competitive landscape is influenced by key players such as Novartis, AstraZeneca, and Bayer, who are investing heavily in research and development to innovate and expand their FGFR inhibitor portfolios. Regulatory frameworks, particularly in North America and Europe, are pivotal in setting the pace for drug approvals, impacting market dynamics. Looking ahead, the FGFR inhibitor market is poised for substantial growth, driven by advancements in biotechnology and personalized medicine. However, challenges such as high treatment costs and stringent regulatory requirements persist. Nonetheless, the increasing incidence of cancer and advancements in genetic research present lucrative opportunities for market expansion.

Geographical Overview:

The Fibroblast Growth Factor Receptor (FGFR) Inhibitor Market is witnessing varied growth patterns across different regions. North America is at the forefront, driven by robust research and development activities. The presence of major pharmaceutical companies and strong healthcare infrastructure further propels market growth. Europe follows closely, with substantial investments in biotechnology and a supportive regulatory framework. The region's emphasis on innovation and advanced therapies enhances its market position. In the Asia Pacific region, the market is expanding rapidly due to increasing healthcare expenditures and rising awareness of targeted therapies. Countries like China and India are making significant strides in biotechnology, contributing to market growth. Latin America presents emerging opportunities, with growing investments in healthcare infrastructure and increasing prevalence of cancer driving demand for FGFR inhibitors. The Middle East & Africa region is gradually recognizing the potential of FGFR inhibitors in addressing unmet medical needs. Investments in healthcare and biotechnology are on the rise, albeit at a slower pace compared to other regions. Overall, the FGFR Inhibitor Market is poised for substantial growth, with regional dynamics playing a crucial role in shaping its trajectory.

Recent Developments:

The Fibroblast Growth Factor Receptor (FGFR) Inhibitor Market has been dynamic in recent months, marked by several pivotal developments. AstraZeneca announced a strategic collaboration with a biotech firm to co-develop a novel FGFR inhibitor, aiming to enhance its oncology portfolio. Bayer AG expanded its FGFR inhibitor research through a joint venture with a leading academic institution, focusing on innovative therapeutic applications. In regulatory news, the FDA granted Fast Track designation to a promising FGFR inhibitor, accelerating its path to market and highlighting its potential impact on cancer treatment. Financially, a prominent pharmaceutical company secured significant investment to advance its FGFR inhibitor pipeline, reflecting investor confidence in the market's growth potential. Lastly, a major player in the industry launched an advanced FGFR inhibitor, showcasing improved efficacy in clinical trials and setting a new benchmark for treatment standards. These developments underscore the market's robust growth trajectory and the increasing focus on targeted cancer therapies.

Key Companies:

Blueprint Medicines, Relay Therapeutics, Deciphera Pharmaceuticals, Mirati Therapeutics, QED Therapeutics, Taiho Oncology, Incyte Corporation, Five Prime Therapeutics, Zymeworks, CStone Pharmaceuticals, Fosun Pharma, Hutchison China Medi Tech, I- Mab Biopharma, Chia Tai Tianqing Pharmaceutical Group, Betta Pharmaceuticals, Ascentage Pharma, Jiangsu Hengrui Medicine, Innovent Biologics, Eisai Co. Ltd., Array Bio Pharma

Trends and Drivers:

The Fibroblast Growth Factor Receptor (FGFR) Inhibitor Market is experiencing robust growth, propelled by advancements in precision medicine and targeted cancer therapies. The increasing prevalence of cancer, particularly those driven by FGFR gene mutations, is a significant market driver. As healthcare systems worldwide prioritize personalized treatment approaches, FGFR inhibitors are gaining traction as a crucial component in oncological care. Key trends include the development of next-generation FGFR inhibitors with improved specificity and reduced side effects. Pharmaceutical companies are investing heavily in research and development to enhance the efficacy and safety profiles of these inhibitors. Additionally, strategic collaborations and partnerships are emerging as companies seek to expand their therapeutic portfolios and accelerate drug development timelines. Moreover, regulatory agencies are streamlining approval processes, recognizing the urgent need for innovative cancer treatments. This regulatory support is fostering a conducive environment for market growth. Opportunities are abundant in emerging markets where healthcare infrastructure is expanding, and there is an increasing focus on improving cancer care. Companies that can navigate these diverse markets and address unmet clinical needs are well-positioned to capture significant market share.

Restraints and Challenges:

The Fibroblast Growth Factor Receptor (FGFR) Inhibitor Market is currently facing several significant restraints and challenges. A primary challenge is the high cost of drug development and clinical trials, which can be prohibitive for smaller companies. This financial burden limits innovation and delays the introduction of new treatments. Additionally, regulatory hurdles are formidable, as stringent approval processes can extend time-to-market and inflate costs. Another restraint is the potential for adverse side effects, which can deter patient adoption and lead to increased scrutiny from regulatory bodies. Market penetration is further hindered by competition from alternative therapies, which may offer similar efficacy with fewer side effects. Finally, there is a lack of awareness and understanding among healthcare providers and patients, which can stifle demand and slow the adoption of FGFR inhibitors. These challenges collectively impede the market's growth and accessibility.

Sources:

National Institutes of Health (NIH), European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA), World Health Organization (WHO), National Cancer Institute (NCI), European Society for Medical Oncology (ESMO), American Association for Cancer Research (AACR), International Cancer Research Partnership (ICRP), Cancer Research UK, The American Society of Clinical Oncology (ASCO), International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Health Canada, Medicines and Healthcare Products Regulatory Agency (MHRA), Japan Pharmaceuticals and Medical Devices Agency (PMDA), Australian Therapeutic Goods Administration (TGA), The American Association of Pharmaceutical Scientists (AAPS), International Conference on Molecular Targets and Cancer Therapeutics, World Cancer Congress, The European Conference on Cancer Research, The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting

Research Scope:

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1: Fibroblast Growth Factor Receptor Inhibitor Market Overview

2: Executive Summary

3: Premium Insights on the Market

4: Fibroblast Growth Factor Receptor Inhibitor Market Outlook

5: Fibroblast Growth Factor Receptor Inhibitor Market Strategy

6: Fibroblast Growth Factor Receptor Inhibitor Market Size

7: Fibroblast Growth Factor Receptor Inhibitor Market, by Type

8: Fibroblast Growth Factor Receptor Inhibitor Market, by Product

9: Fibroblast Growth Factor Receptor Inhibitor Market, by Application

10: Fibroblast Growth Factor Receptor Inhibitor Market, by End User

11: Fibroblast Growth Factor Receptor Inhibitor Market, by Technology

12: Fibroblast Growth Factor Receptor Inhibitor Market, by Process

13: Fibroblast Growth Factor Receptor Inhibitor Market, by Deployment

14: Fibroblast Growth Factor Receptor Inhibitor Market, by Component

15: Fibroblast Growth Factor Receptor Inhibitor Market, by Functionality

16: Fibroblast Growth Factor Receptor Inhibitor Market, by Region

17: Competitive Landscape

18: Company Profiles

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기